SI3705488T1 - Nevroaktivni steroidi, sestavki in uporaba le-teh - Google Patents

Nevroaktivni steroidi, sestavki in uporaba le-teh

Info

Publication number
SI3705488T1
SI3705488T1 SI201531879T SI201531879T SI3705488T1 SI 3705488 T1 SI3705488 T1 SI 3705488T1 SI 201531879 T SI201531879 T SI 201531879T SI 201531879 T SI201531879 T SI 201531879T SI 3705488 T1 SI3705488 T1 SI 3705488T1
Authority
SI
Slovenia
Prior art keywords
compositions
neuroactive steroids
neuroactive
steroids
Prior art date
Application number
SI201531879T
Other languages
English (en)
Inventor
Gabriel Martinez Botella
Boyd L. Harrison
Albert Jean Robichaud
Francesco G. Salituro
Richard Thomas Beresis
Original Assignee
Sage Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics, Inc. filed Critical Sage Therapeutics, Inc.
Publication of SI3705488T1 publication Critical patent/SI3705488T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0018Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0059Estrane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
SI201531879T 2014-05-29 2015-05-29 Nevroaktivni steroidi, sestavki in uporaba le-teh SI3705488T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014078820 2014-05-29
EP20171670.1A EP3705488B1 (en) 2014-05-29 2015-05-29 Neuroactive steroids, compositions and uses thereof

Publications (1)

Publication Number Publication Date
SI3705488T1 true SI3705488T1 (sl) 2022-10-28

Family

ID=54698130

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531879T SI3705488T1 (sl) 2014-05-29 2015-05-29 Nevroaktivni steroidi, sestavki in uporaba le-teh
SI201531252T SI3149018T1 (sl) 2014-05-29 2015-05-29 Nevroaktivni steroidi, sestavki in uporaba le-teh

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201531252T SI3149018T1 (sl) 2014-05-29 2015-05-29 Nevroaktivni steroidi, sestavki in uporaba le-teh

Country Status (26)

Country Link
US (5) US20180179247A1 (sl)
EP (3) EP3149018B1 (sl)
JP (4) JP6652934B2 (sl)
KR (2) KR20240066304A (sl)
CN (3) CN114133423A (sl)
AR (2) AR100691A1 (sl)
AU (4) AU2015266447A1 (sl)
CA (1) CA2949720A1 (sl)
CY (1) CY1124109T1 (sl)
DK (2) DK3705488T3 (sl)
ES (2) ES2927007T3 (sl)
HR (2) HRP20221294T1 (sl)
HU (2) HUE059829T2 (sl)
IL (3) IL292461B2 (sl)
JO (1) JO3691B1 (sl)
LT (2) LT3149018T (sl)
MX (4) MX2016015532A (sl)
PH (1) PH12016502342A1 (sl)
PL (2) PL3149018T3 (sl)
PT (2) PT3149018T (sl)
RS (2) RS63554B1 (sl)
RU (2) RU2019126637A (sl)
SG (2) SG11201609813XA (sl)
SI (2) SI3705488T1 (sl)
TW (1) TW201625661A (sl)
WO (1) WO2015180679A1 (sl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101405545B1 (ko) 2005-11-28 2014-07-03 마리누스 파마슈티컬스 ganaxolone 제형, 이의 제조방법 및 용도
CA3152410A1 (en) 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
CN112110976B (zh) 2013-04-17 2023-08-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CN113527400A (zh) 2013-04-17 2021-10-22 萨奇治疗股份有限公司 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
LT3021852T (lt) 2013-07-19 2021-04-12 Sage Therapeutics, Inc. Neuroaktyvūs steroidai, jų kompozicijos ir panaudojimas
DK3488852T3 (da) 2013-08-23 2021-02-01 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser deraf
SI3705488T1 (sl) * 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
TW202235090A (zh) 2014-10-16 2022-09-16 美商賽吉醫療公司 用於治療中樞神經系統(cns)病症之組合物及方法
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
HUE054092T2 (hu) 2015-01-26 2021-08-30 Sage Therapeutics Inc Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
JP2018530585A (ja) 2015-10-16 2018-10-18 マリナス ファーマシューティカルズ インコーポレイテッド ナノ粒子を含む注射可能な神経ステロイド製剤
WO2017156103A1 (en) * 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA3030420A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
IL264129B2 (en) * 2016-07-11 2024-05-01 Sage Therapeutics Inc C20, C17 and C21 converted neuroactive steroids and methods of using them
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP2021505608A (ja) 2017-12-08 2021-02-18 セージ セラピューティクス, インコーポレイテッド CNS障害を処置するためのジュウテリウム化された21−[4−シアノ−ピラゾール−1−イル]−19−ノル−プレガン−3.α−オール−20−オン誘導体
CN114805462A (zh) * 2018-02-11 2022-07-29 江苏豪森药业集团有限公司 一种甾族类衍生物调节剂及其制备方法和应用
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP3911331A4 (en) * 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
BR112021024033A2 (pt) 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
WO2021023213A1 (zh) 2019-08-07 2021-02-11 上海翰森生物医药科技有限公司 一种甾族类衍生物调节剂的盐及其晶型
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
MX2022006014A (es) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolona para uso en el tratamiento del complejo de esclerosis tuberosa.
IL304080A (en) 2021-01-28 2023-08-01 Sage Therapeutics Inc Use of neuroactive steroids to treat sexual dysfunction
KR20240037975A (ko) * 2021-07-28 2024-03-22 세이지 테라퓨틱스, 인크. 신경활성 스테로이드의 결정질 형태
WO2023164387A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634717A1 (de) * 1986-10-11 1988-04-14 Dynamit Nobel Ag Verfahren zur herstellung von 5-methyltetrazol
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
IL112638A (en) * 1994-02-14 2003-10-31 Cocensys Inc 3alpha-HYDROXYLATED PREGNANE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
WO1998005337A1 (en) * 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
WO2000066614A1 (en) * 1999-04-29 2000-11-09 Purdue Pharma Ltd. 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
WO2004036372A2 (en) * 2002-10-15 2004-04-29 Medtronic Inc. Scoring of sensed neurological signals for use with a medical device system
US7729773B2 (en) * 2005-10-19 2010-06-01 Advanced Neuromodualation Systems, Inc. Neural stimulation and optical monitoring systems and methods
CA3152410A1 (en) * 2011-10-14 2013-04-18 Sage Therapeutics, Inc. 3,3-disubstituted 19-nor pregnane compounds, compositions, and uses thereof for the treatment of cns related disorders
SI3705488T1 (sl) * 2014-05-29 2022-10-28 Sage Therapeutics, Inc. Nevroaktivni steroidi, sestavki in uporaba le-teh
ES2808855T3 (es) * 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC

Also Published As

Publication number Publication date
BR112016027508A2 (pt) 2018-06-26
RU2016151727A (ru) 2018-07-02
RS63554B1 (sr) 2022-09-30
KR20170003706A (ko) 2017-01-09
AU2023285755A1 (en) 2024-01-18
AU2015266447A1 (en) 2016-12-01
EP3705488A1 (en) 2020-09-09
NZ764941A (en) 2023-11-24
MX2016015532A (es) 2017-02-27
NZ726260A (en) 2023-11-24
KR20230021165A (ko) 2023-02-13
EP3149018A4 (en) 2017-12-06
NZ764921A (en) 2023-11-24
IL304033A (en) 2023-08-01
DK3149018T3 (da) 2020-07-20
AU2019279910A1 (en) 2020-01-16
SG11201609813XA (en) 2016-12-29
AU2019279910B2 (en) 2021-07-22
JO3691B1 (ar) 2020-08-27
US20210061850A1 (en) 2021-03-04
CA2949720A1 (en) 2015-12-03
HRP20201126T1 (hr) 2020-12-11
JP2021130696A (ja) 2021-09-09
EP4144746A1 (en) 2023-03-08
PT3705488T (pt) 2022-09-30
KR102494061B1 (ko) 2023-01-31
JP2020073577A (ja) 2020-05-14
US20240076310A1 (en) 2024-03-07
AU2021204410B2 (en) 2023-09-21
CN114369135A (zh) 2022-04-19
JP2017516793A (ja) 2017-06-22
KR20240066304A (ko) 2024-05-14
LT3149018T (lt) 2020-08-10
JP2023123878A (ja) 2023-09-05
IL248948B (en) 2022-09-01
MX2023004352A (es) 2023-05-08
JP7386204B2 (ja) 2023-11-24
CN114133423A (zh) 2022-03-04
RS60529B1 (sr) 2020-08-31
JP6892936B2 (ja) 2021-06-23
ES2927007T3 (es) 2022-10-31
IL292461B1 (en) 2023-11-01
IL292461A (en) 2022-06-01
EP3149018B1 (en) 2020-04-29
SI3149018T1 (sl) 2020-10-30
MX2021005106A (es) 2021-06-15
IL292461B2 (en) 2024-03-01
HRP20221294T1 (hr) 2023-03-03
AR121661A2 (es) 2022-06-29
AR100691A1 (es) 2016-10-26
CN106661078A (zh) 2017-05-10
TW201625661A (zh) 2016-07-16
WO2015180679A1 (en) 2015-12-03
ES2805598T3 (es) 2021-02-12
LT3705488T (lt) 2022-09-26
US20180179247A1 (en) 2018-06-28
US20200165291A1 (en) 2020-05-28
JP6652934B2 (ja) 2020-02-26
EP3705488B1 (en) 2022-08-03
EP3149018A1 (en) 2017-04-05
US20210061849A1 (en) 2021-03-04
HUE050028T2 (hu) 2021-12-28
PT3149018T (pt) 2020-07-21
IL248948A0 (en) 2017-01-31
PL3149018T3 (pl) 2021-01-25
CY1124109T1 (el) 2022-03-24
RU2016151727A3 (sl) 2018-12-03
DK3705488T3 (da) 2022-10-03
PL3705488T3 (pl) 2022-12-05
AU2021204410A1 (en) 2021-07-22
MX2021005099A (es) 2021-06-15
TW202231652A (zh) 2022-08-16
RU2019126637A (ru) 2019-10-03
PH12016502342A1 (en) 2017-02-13
HUE059829T2 (hu) 2022-12-28
SG10201803812TA (en) 2018-06-28
RU2699359C2 (ru) 2019-09-05

Similar Documents

Publication Publication Date Title
IL292461A (en) Neuroactive steroids, preparations and their uses
IL285703A (en) Neuroactive steroids, preparations and their uses
HK1258616A1 (zh) 神經活性類固醇、組合物、及其用途
HK1225977B (zh) 神經活性類固醇、組合物和其用途
EP3258939A4 (en) Neuroactive steroids, compositions, and uses thereof
HK1220472A1 (zh) 神經活性類固醇、組合物、及其用途
HUE053900T2 (hu) Neuroaktív szteroidok, kompozíciók, és azok alkalmazásai
IL250568A0 (en) Anti-methanogenic preparations and their uses